NCT04327271

Brief Summary

Voluntary medical male circumcision (alternatively abbreviated in the literature as VMMC or MC) is a critical HIV prevention intervention with global support for expansion across sub-Saharan Africa (SSA). MC is safe: routine programs in SSA report adverse event (AE) rates well under 2%. Nevertheless, global MC guidelines require one or more follow-up visits within 14 days for AE detection. Our prior research in Zimbabwe employed two-way texting (2wT) between patients and providers to focus follow-up on men with potential AEs, allowing men healing without complication to opt-out of routine post-operative visits. 2wT safely reduced client visits by 85%, suggesting that 2wT can make MC services dramatically more efficient while maintaining safety. In the Republic of South Africa (RSA), high-volume urban clinics, remote service delivery, and low AE identification threaten quality at scale. Across more than 500,000 annual MCs performed, up to 1 million multi-stage, unnecessary MC reviews are likely conducted. RSA pressure for MC expansion and severe health system constraints, combined with good cell coverage, suggest 2wT's impact would be significant for MC care quality and efficiency, especially in rural areas. A randomized control trial (RCT) will rigorously evaluate how 2wT improves AE ascertainment and follow-up efficiency in urban and rural clinics. We aim to conduct an RCT to determine how 2wT increases AE ascertainment while reducing workload in the RSA implementation context. While the overall protocol covers multiple components over a 5-year study, this registration is specific to the RCT, aim 1.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,093

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 20, 2020

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 31, 2020

Completed
1.2 years until next milestone

Study Start

First participant enrolled

June 7, 2021

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 3, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 24, 2022

Completed
10 months until next milestone

Results Posted

Study results publicly available

January 27, 2023

Completed
Last Updated

January 27, 2023

Status Verified

January 1, 2023

Enrollment Period

8 months

First QC Date

March 20, 2020

Results QC Date

June 10, 2022

Last Update Submit

January 4, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Cumulative Percentage of Patients With an Adverse Event (AE) (Moderate or Severe) on or Before Day 14 Visit

    AE rates are a global indicator of VMMC quality. This is a standard WHO and US PEPFAR government indicator as indicated in the attached reference material: PEPFAR's Best Practices for Voluntary Medical Male Circumcision Site Operations. Incidence of AEs before Day 14 will be extracted from routine VMMC data for both 2wT and control. Incident AEs on Day 14 will be identified, classified, and graded for severity using routine Ministry of Health protocols and recorded on routine VMMC AE forms. The investigators will compare cumulative rates of any moderate or severe AE on or before Day 14 between groups using Fisher's exact test as the expected number of AEs is low. The rates will be calculated per arm as: (num moderate plus severe AEs)/(total num VMMC clients who attend 2, 7 or 14 Day follow-up visit). Multivariate logistic regression models (any AE versus none) will quantify the magnitude of difference, adjusting for any potential confounders

    Any AE before, and including, up to 22 days post VMMC to allow for logistical issues delaying attendance of the Day 14 visit

  • Number of Non-study In-person Visits

    To determine follow-up visit reduction, the investigators will compare the number of in- person visits for intervention and control using a t-test.

    Less than or equal to 42 days post-operative

Secondary Outcomes (2)

  • Percent of Adverse Events (AE) Identified /on/ Day 14 Visit

    AEs identified during Day 14 visits that occurred only in the window between post-operative days 13-22

  • Number VMMC-related Severe Adverse Events Over 22 Post-operative Days

    Within 22 days post operative

Study Arms (2)

Text-based VMMC follow-up

EXPERIMENTAL

Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.

Behavioral: Text-based VMMC follow-up

Routine VMMC follow-up care

NO INTERVENTION

Routine VMMC follow up care with in person visits according to national guidelines.

Interventions

2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts or return for any visit by day 14, they will be traced by SMS, phone or home visit. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 21, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.

Text-based VMMC follow-up

Eligibility Criteria

Age18 Years - 75 Years
Sexall(Gender-based eligibility)
Gender Eligibility DetailsOnly men will be enrolled in the study on male circumcision. Health care workers/key informants may be male or female
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For VMMC clients:
  • are at least 18 years of age or over
  • Possession of own phone at enrollment
  • Willing to respond to daily text
  • Provides contact details (phone, address)
  • Undergoes surgical MC
  • Willing to follow NDoH VMMC protocols
  • No interoperative AE
  • Informed consent
  • Receives confirmed 2wT enrollment text.

You may not qualify if:

  • For VMMC clients:
  • Not meeting above requirements
  • Men without cell phones
  • Men who chose PrePex device-based VMMC
  • Inter-operative AE during VMMC
  • No informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Mogwase

Mogwase, Bojanala, South Africa

Location

Bafokeng

Phokeng, Bojanala, South Africa

Location

Tsakane Clinic

Brakpan, Gauteng, South Africa

Location

Katlehong North Clinic

Katlehong, Gauteng, South Africa

Location

Winnie Mandela Male Health Clinic

Tembisa, Gauteng, 1632, South Africa

Location

Nchabeleng Community Health Centre

Apel, Limpopo, 0739, South Africa

Location

Philadelphia Hospital

Dennilton, Limpopo, 1030, South Africa

Location

Dilokong Hospital

Driekop, Limpopo, 1129, South Africa

Location

Matlala Hospital

Marble Hall, Limpopo, 0450, South Africa

Location

Related Publications (6)

  • Feldacker C, Murenje V, Barnhart S, Xaba S, Makunike-Chikwinya B, Holeman I, Tshimanga M. Reducing provider workload while preserving patient safety via a two-way texting intervention in Zimbabwe's voluntary medical male circumcision program: study protocol for an un-blinded, prospective, non-inferiority, randomized controlled trial. Trials. 2019 Jul 23;20(1):451. doi: 10.1186/s13063-019-3470-9.

    PMID: 31337414BACKGROUND
  • Feldacker C, Murenje V, Holeman I, Xaba S, Makunike-Chikwinya B, Korir M, Gundidza PT, Holec M, Barnhart S, Tshimanga M. Reducing Provider Workload While Preserving Patient Safety: A Randomized Control Trial Using 2-Way Texting for Postoperative Follow-up in Zimbabwe's Voluntary Medical Male Circumcision Program. J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):16-23. doi: 10.1097/QAI.0000000000002198.

    PMID: 31809358BACKGROUND
  • Feldacker C, Holeman I, Murenje V, Xaba S, Korir M, Wambua B, Makunike-Chikwinya B, Holec M, Barnhart S, Tshimanga M. Usability and acceptability of a two-way texting intervention for post-operative follow-up for voluntary medical male circumcision in Zimbabwe. PLoS One. 2020 Jun 16;15(6):e0233234. doi: 10.1371/journal.pone.0233234. eCollection 2020.

    PMID: 32544161BACKGROUND
  • Babigumira JB, Barnhart S, Mendelsohn JM, Murenje V, Tshimanga M, Mauhy C, Holeman I, Xaba S, Holec MM, Makunike-Chikwinya B, Feldacker C. Cost-effectiveness analysis of two-way texting for post-operative follow-up in Zimbabwe's voluntary medical male circumcision program. PLoS One. 2020 Sep 30;15(9):e0239915. doi: 10.1371/journal.pone.0239915. eCollection 2020.

    PMID: 32997710BACKGROUND
  • Setswe G, Day S, Ndebele F, Pienaar J, Ncube V, Feldacker C. Finding the balance between rigour and relevance: implementing adaptations to the implementation of a pragmatic randomised controlled trial of a two-way texting intervention for voluntary medical male circumcision in South Africa. BMJ Open. 2025 Apr 28;15(4):e091934. doi: 10.1136/bmjopen-2024-091934.

  • Feldacker C, Pienaar J, Wasunna B, Ndebele F, Khumalo C, Day S, Tweya H, Oni F, Sardini M, Adhikary B, Waweru E, Wafula MB, Dixon A, Jafa K, Su Y, Sherr K, Setswe G. Expanding the Evidence on the Safety and Efficiency of 2-Way Text Messaging-Based Telehealth for Voluntary Medical Male Circumcision Follow-up Compared With In-Person Reviews: Randomized Controlled Trial in Rural and Urban South Africa. J Med Internet Res. 2023 May 9;25:e42111. doi: 10.2196/42111.

Related Links

Limitations and Caveats

Mild AEs are not reported to the Ministry of Health nor in the study. Notifiable AEs could be underreported in either group: men could seek care for AEs at another clinic, treat themselves and not report it, or otherwise heal without intervention. Men in the 2wT arm received enhanced AE identification education with illustrative photos to explain the words of the daily response, a bias that could have increased AE identification as compared to routine. Longer term outcomes are unknown.

Results Point of Contact

Title
Caryl Feldacker
Organization
University of Washington

Study Officials

  • Caryl Feldacker, PhD, MPH

    University of Washington

    PRINCIPAL INVESTIGATOR
  • Geoffrey Setswe, DrPH, MPH

    Aurum Institute

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: 2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, School of Public Health, Global Health

Study Record Dates

First Submitted

March 20, 2020

First Posted

March 31, 2020

Study Start

June 7, 2021

Primary Completion

February 3, 2022

Study Completion

March 24, 2022

Last Updated

January 27, 2023

Results First Posted

January 27, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

We do not plan to share IPD with other researchers.

Locations